Katkin Keith
- SEC CIK
- 0001314596
In the past year, 1 open-market sale filing worth $128.2K and no purchases.
Current role at each company
- EBS Emergent BioSolutions Inc.Directoras of May 4, 2026
- SNDX Syndax Pharmaceuticals IncDirectoras of Feb 6, 2026
- ELDN Eledon Pharmaceuticals, Inc.Directoras of Jan 16, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $128.2K
- 1 filing
- Net
- −$128.2K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Katkin Keith as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
EBS Emergent BioSolutions Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 (view filing) | Apr 30 | 4 days | Katkin KeithDirector | SSale | −15.5K | $8.28 | −$128.2K | −13.9%96.3K after | 10b5-1 |
| May 28, 2025 (view filing) | May 23 | 5 days | Katkin KeithDirector | SSale | −7.84K | $6.30 | −$49.4K | −8.3%86.4K after | 10b5-1 |
SNDX Syndax Pharmaceuticals Inc
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2025 (view filing) | May 19 | Same day | Katkin KeithDirector | PPurchase | +10.0K | $9.11 | +$91.1K | +11.1%100.0K after | |
| Oct 7, 2022 (view filing) | Oct 6 | 1 day | Katkin KeithDirector | SSale | −29.9K | $25.90 | −$774.4K | −48.3%32.0K after | 2 lots |
| Oct 4, 2022 (view filing) | Sep 30-Oct 4 | 4 days | Katkin KeithDirector | SSale | −4.10K | $25.06 | −$102.8K | −11.4%32.0K after | 6 lots |